A Second Ascent of Chemistry’s Mt. Everest
News Dec 18, 2012
In science’s equivalent of ascending Mt. Everest, researchers are reporting success in one of the most difficult challenges in synthetic chemistry — a field in which scientists reproduce natural and other substances from jars of chemicals in a lab.
The feat, reported in the Journal of the American Chemical Society, involved synthesis of a rare substance with promising in vitro anti-cancer effects found naturally in tiny amounts in a Chinese medicinal herb.
Samuel J. Danishefsky and Feng Peng explain that maoecrystal V occurs naturally in a plant growing in China’s Yunnan province. Practitioners of Chinese traditional medicine have used the herb, called Isodon eriocalyx Hara, for hundreds of years. Scientists isolated maoecrystal V in 1994 and found that it has anti-cancer effects that warrant further examination. Large amounts would be needed to do so. However, the herb contains only small amounts of the material. In one experiment, it took more than 26 pounds of dried leaves to produce 0.00017637 oz. of maoecrystal V. In 2010, the first group of scientists succeeded in making maoecrystal V in a lab. Now, a second group has found a new route to the potential anti-cancer compound.
Danishefsky and Peng describe their approach as providing the basis for a synthesis that may help scientists develop a practical route to the substance for drug development and other research. It yielded a mixture of the two enantiomeric forms of maoecrystal V. They are pursuing several improvements, including a way to control the reactions to yield only a single enantiomer of the substance.
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of LondonNews
The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.READ MORE